Vivity Study in Taiwan (NCT06719882) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Vivity Study in Taiwan
Taiwan100 participantsStarted 2022-12-15
Plain-language summary
The aim of study is to evaluate the quality of vision after bilateral Vivity or Vivity toric EDOF IOLs implantation in Taiwan.
Who can participate
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Patients with age-related cataract requiring surgery treatment
* Patient who received bilateral, uneventful implantation of Vivity IOLs
* Patient's IOL power is between 10-30D, and T2-T6 for toric correction
* Cataract grade 0\~3 based on the Wisconsin cataract grading system
• Exclusion criteria:
* Cataract grade 4\~5 based on the Wisconsin cataract grading system
* Patient's IOL power is outside of 10-30D or T2-T6 for toric correction
* Patient with the following ocular comorbidities:
* Corneal opacities or irregularities;
* Severe dry eye;
* Amblyopia;
* Glaucoma;
* Non-dilating pupil;
* History of intraocular surgery, laser therapy, or retinopathy;
* Optic nerve or macular diseases;
* Uncontrolled diabetic mellitus or systemic immune disease;
* Refusal or unable to maintain follow-up
What they're measuring
1
Visual acuity (LogMAR)
Timeframe: From enrollment to the end of treatment at 3 months